Fig 1: FH is expressed in human glioma and correlates with disease severity. FH is produced in human lower-grade glioma (A) and GBM (B). C, FH expression correlates with decreased overall survival (C) and disease-free survival (D) of patients with glioma. Expression of FH correlates with primary therapy outcome (E), cancer type (F), neoplasm histological grade (G), new neoplasm event post-initial therapy (H), and IDH1 mutation rate (I). The worse survival rendered by FH is ICOS-dependent (J) but not dependent on ICOSL (K). The survival estimates and correlation with other clinical parameters based on mRNA and survival data of n = 509 (C, J, and K), n = 472 (D) patients from TCGA provisional dataset brain lower-grade glioma, analyzed with cBioPortal. Statistical tests: logrank test (C, D, J, and K), χ2 test (E–I). Representative picture of n = 2 (A), n = 3 patients (B).
Fig 2: FH is expressed in human glioma and correlates with disease severity. FH is produced in human lower-grade glioma (A) and GBM (B). C, FH expression correlates with decreased overall survival (C) and disease-free survival (D) of patients with glioma. Expression of FH correlates with primary therapy outcome (E), cancer type (F), neoplasm histological grade (G), new neoplasm event post-initial therapy (H), and IDH1 mutation rate (I). The worse survival rendered by FH is ICOS-dependent (J) but not dependent on ICOSL (K). The survival estimates and correlation with other clinical parameters based on mRNA and survival data of n = 509 (C, J, and K), n = 472 (D) patients from TCGA provisional dataset brain lower-grade glioma, analyzed with cBioPortal. Statistical tests: logrank test (C, D, J, and K), χ2 test (E–I). Representative picture of n = 2 (A), n = 3 patients (B).
Supplier Page from Abcam for Recombinant human ICOS Ligand/ICOSL protein (Active)